假设所有3170万股配售股份获悉数认购，于配售完成后，所得款项总额将为19.43亿港元，配售所得款项净额(扣除配售佣金及其他相关开支及专业费用后)估计为19.24亿港元。Akeso (09926) rose by over 3% in the morning session, as of the publication, up by 2.71%, at HKD 66.25, with a turnover of 1.069 billion Hong Kong dollars.
According to the Securities Times APP, Akeso (09926) rose by over 3% in the morning session, as of the publication, up by 2.71%, at HKD 66.25, with a turnover of 1.069 billion Hong Kong dollars.
On the news front, Akeso issued an announcement on October 11, 2024. The company entered into a placement agreement with a placement agent. Accordingly, the company conditionally agreed to place a total of 31.7 million shares through the placement agent at a price of HKD 61.28 per share to no fewer than six placees. The placement price of HKD 61.28 per share was determined by the company and the placement agent after fair negotiation, representing a discount of approximately 4.99% compared to the closing price of HKD 64.50 per share reported to the Stock Exchange on October 10, 2024 (i.e., the last complete trading day before the placement agreement date).
Assuming all 31.7 million placement shares are fully subscribed, the total amount raised after the placement will be HK$1.943 billion, with an estimated net proceeds from the placement (after deducting placement commission and other related expenses and professional fees) of approximately HK$1.924 billion.
The announcement stated that the net proceeds from the placement will be used for the following purposes: 70% for global and China clinical development of core products, as well as other clinical pipeline products in oncology and immunology; 20% for the commercialization of existing approved products; 10% for general corporate purposes.
